Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2009-4-29
pubmed:databankReference
pubmed:abstractText
Tapentadol is a novel, centrally acting analgesic with two mechanisms of action, mu-opioid receptor agonism and norepinephrine reuptake inhibition, in a single molecule. This phase III, randomized, double-blind, active-controlled study evaluated the tolerability of tapentadol immediate release (IR) and oxycodone IR for low back pain or osteoarthritis pain (hip or knee), using flexible dosing over 90 days.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1473-4877
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1095-104
pubmed:meshHeading
pubmed-meshheading:19301989-Adult, pubmed-meshheading:19301989-Aged, pubmed-meshheading:19301989-Aged, 80 and over, pubmed-meshheading:19301989-Analgesics, pubmed-meshheading:19301989-Double-Blind Method, pubmed-meshheading:19301989-Drug Administration Schedule, pubmed-meshheading:19301989-Drug Compounding, pubmed-meshheading:19301989-Female, pubmed-meshheading:19301989-Humans, pubmed-meshheading:19301989-Low Back Pain, pubmed-meshheading:19301989-Male, pubmed-meshheading:19301989-Middle Aged, pubmed-meshheading:19301989-Models, Biological, pubmed-meshheading:19301989-Osteoarthritis, Hip, pubmed-meshheading:19301989-Osteoarthritis, Knee, pubmed-meshheading:19301989-Oxycodone, pubmed-meshheading:19301989-Pain, pubmed-meshheading:19301989-Phenols, pubmed-meshheading:19301989-Time Factors, pubmed-meshheading:19301989-Treatment Outcome
pubmed:year
2009
pubmed:articleTitle
Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.
pubmed:affiliation
Gold Coast Research, LLC, Plantation, FL, USA.
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III